Vir Biotechnology (NASDAQ:VIR) reported quarterly earnings results on February 23, 2026 that exceeded analyst expectations.
The Healthcare company reported earnings per share of $-0.31, beating the consensus estimate of $-0.47 by $0.16 per share. Revenue came in at $64.1M, beating the estimate of $19.4M.
Vir Biotechnology's stock moved following the earnings release. The stock currently trades at $10.07 with a market capitalization of $923.0M.